Clinical observation of Sweet Dream Oral Liquid curing deficiency of spleen and kidney style MCI / 中草药

ABSTRACT

Objective To observe the clinical effect of Sweet Dream Oral Liquid on the mild cognitive impairment (MCI) patients of spleen and kidney deficiency. Methods A total of 102 patients with MCI were randomly divided into two groups, the treatment group with 53 patients and the control group with 49 patients. Both groups were given Citicoline Sodium Tablets for 8 weeks. The treatment group was given Sweet Dream Oral Liquid extra. Mini-mental state examination (MMSE), Transcranial Doppler (TCD) and Traditional Chinese Medicine Syndrome Score (TCMSS) were performed before and after the treatment. Compliance and adverse reactions for both groups were observed during the treatment. Results MMSE improved after the treatment for both groups; Especially, MMSE of the treatment group improved more obviously (P < 0.01); The difference between the two groups was significant (P < 0.05); For treatment group, the average blood flow velocity (Vm) of the cerebral arteries was increased significantly after the treatment(P < 0.01); Compared with the control group, the difference was obvious (P < 0.05); The total effective rate of the treatment group on spleen and kidney deficiency syndrome was 96.23%. It was 18.37% for the control group. Difference between the two groups was significant (P < 0.01). After the treatment, TCMSS of the treatment group was significantly reduced (P < 0.01); It was a significant difference comparing with the control group (P < 0.01). During the treatment, both groups had a good compliance, no adverse reactions and no shedding patients. Conclusion Sweet Dream Oral Liquid can improve the cognitive function and living quality of the patients with deficiency of spleen and kidney style MCI by reducing TCMSS, improving cerebral hemodynamics and rising MMSE score.